---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274068"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:48:17.058031+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q3 net income $7.3M; initiates first RNA editing clinical program, WVE-006

## Summary
- Net income of $7.3M vs net loss of $39.0M YoY; revenue increase driven by $48.9M in collaboration milestones.
- Cash $139.9M as of Sep 30, plus $7M milestone received in 4Q; runway into 2025.
- Initiated RestorAATion clinical program for WVE-006 (RNA editing for AATD); dosing in 4Q 2023, proof-of-mechanism data in 2024.
- Enrolled 30mg multi-dose cohort of SELECT-HD for WVE-003; data in 2Q 2024 to enable Takeda opt-in.
- Preclinical INHBE siRNA data for obesity; clinical candidate selection in 4Q 2024.

## SEC filing metadata
- accession: 0001193125-23-274068
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312523274068/0001193125-23-274068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312523274068/d243880d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274068
- JSON: https://secwatch.observer/filing/0001193125-23-274068.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274068.txt

## Key facts
- Earnings Releases
  Wave Life Sciences Ltd. reported the third quarter ended September 30, 2023 results: net income Cash and cash equivalents of $140 million as of September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Net income: Cash and cash equivalents of $140 million as of September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523274068/0001193125-23-274068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.